SCHEMBL20600623

SCHEMBL20600623

N#Cc1cccc(-c2nc(N)c3nccn3c2-c2ccc3nccn3c2)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TGFBR1 P36897 2/20 0.44
TGFBR2 P37173 1/20 0.44
DYRK1A Q13627 1/20 0.43
ALDH1A3 P47895 1/20 0.43
TRIM33 Q9UPN9 3/20 0.42
ADORA2A P29274 2/20 0.42
ADORA1 P30542 1/20 0.41
KDM1A O60341 2/20 0.38
PIK3CD O00329 1/20 0.38
ABL1 P00519 1/20 0.38
EGFR P00533 1/20 0.38
HCK P08631 1/20 0.38
SRC P12931 1/20 0.38
KDR P35968 1/20 0.38
PIK3CA P42336 1/20 0.38
MTOR P42345 1/20 0.38
PIK3CG P48736 1/20 0.38
EPHB4 P54760 1/20 0.38
PRKDC P78527 1/20 0.38
PI4KB Q9UBF8 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21630630 0.85 EGLN2 (0.43) TGFBR1TGFBR2DYRK1AALDH1A3TRIM33
SCHEMBL30719044 0.85 EGLN2 (0.43) TGFBR1TGFBR2DYRK1AALDH1A3TRIM33
SCHEMBL20600616 0.85 ADORA2A (0.43) ADORA2AADORA1KDM1APIK3CDABL1
SCHEMBL20600533 0.85 IRAK4 (0.39) TGFBR1ADORA2AADORA1KDM1APIK3CD
SCHEMBL20600527 0.85 TGFBR1 (0.48) TGFBR1TGFBR2DYRK1AADORA2AADORA1
SCHEMBL20600532 0.81 ADORA2A (0.46) ADORA2AADORA1KDM1APIK3CDABL1
SCHEMBL20600425 0.80 ADORA2A (0.49) TGFBR1ADORA2AADORA1PIK3CDABL1
SCHEMBL20600474 0.80 TGFBR1 (0.60) TGFBR1DYRK1AADORA2AADORA1GRIA1
SCHEMBL20600542 0.79 ADORA2A (0.48) TGFBR1DYRK1AADORA2AADORA1KDM1A
SCHEMBL20600520 0.79 ADORA2A (0.42) ADORA2AADORA1KDM1APIK3CDABL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200369665-A1 IMIDAZO[1,2-A]PYRAZINE MODULATORS OF THE ADENOSINE A2A RECEPTOR Ryvu Therapeutics S.A. (PL) 2020-11-26 US claimed
EP-3645536-A1 IMIDAZO[1,2-A]PYRAZINE MODULATORS OF THE ADENOSINE A2A RECEPTOR Ryvu Therapeutics S.A. (PL) 2020-05-06 EP claimed
CN-110809577-A Modulators of adenosine A2A receptor 雷沃医疗有限公司 2020-02-18 CN claimed
WO-2019002606-A1 IMIDAZO[1,2-A]PYRAZINE MODULATORS OF THE ADENOSINE A2A RECEPTOR SELVITA S.A. (PL) 2019-01-03 WO claimed
US-20200369665-A1 IMIDAZO[1,2-A]PYRAZINE MODULATORS OF THE ADENOSINE A2A RECEPTOR Ryvu Therapeutics S.A. (PL) 2020-11-26 US disclosed
US-20200369665-A1 IMIDAZO[1,2-A]PYRAZINE MODULATORS OF THE ADENOSINE A2A RECEPTOR Ryvu Therapeutics S.A. (PL) 2020-11-26 US disclosed
EP-3645536-A1 IMIDAZO[1,2-A]PYRAZINE MODULATORS OF THE ADENOSINE A2A RECEPTOR Ryvu Therapeutics S.A. (PL) 2020-05-06 EP disclosed
CN-110809577-A Modulators of adenosine A2A receptor 雷沃医疗有限公司 2020-02-18 CN disclosed
WO-2019002606-A1 IMIDAZO[1,2-A]PYRAZINE MODULATORS OF THE ADENOSINE A2A RECEPTOR SELVITA S.A. (PL) 2019-01-03 WO disclosed
WO-2019002606-A1 IMIDAZO[1,2-A]PYRAZINE MODULATORS OF THE ADENOSINE A2A RECEPTOR SELVITA S.A. (PL) 2019-01-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200369665-A1 IMIDAZO[1,2-A]PYRAZINE MODULATORS OF THE ADENOSINE A2A RECEPTOR ADORA2A, ADORA1, ADORA3 TGFBR1 1069/4885TGFBR2 1646/4885DYRK1A 1125/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.